Arthur A Vandenbark

List of Publications by Year
in descending order

125	7,262	76196	60497
papers	citations	40 h-index	81 g-index

126	126	126	6132
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs. Life Sciences, 2022, 294, 120383.	2.0	1
2	â€œNear Cureâ€•treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct. Cellular Immunology, 2022, 378, 104561.	1.4	3
3	Sex differences in EAE reveal common and distinct cellular and molecular components. Cellular Immunology, 2021, 359, 104242.	1.4	30
4	Major histocompatibility complex Class II-based therapy for stroke. Brain Circulation, 2021, 7, 37.	0.7	3
5	Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease. Frontiers in Neurology, 2021, 12, 672455.	1.1	30
6	Brief report: Enhanced DRÎ±1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice. Cellular Immunology, 2021, 370, 104439.	1.4	5
7	Microglia and astrocyte involvement in neurodegeneration and brain cancer. Journal of Neuroinflammation, 2021, 18, 298.	3.1	32
8	A Novel Partial MHC Class II Construct, DRmQ, Inhibits Central and Peripheral Inflammatory Responses to Promote Neuroprotection in Experimental Stroke. Translational Stroke Research, 2020, 11, 831-836.	2.3	19
9	Partial MHC/neuroantigen peptide constructs attenuate methamphetamine-seeking and brain chemokine (Câ€“C motif) ligand 2 levels in rats. European Journal of Pharmacology, 2020, 880, 173175.	1.7	3
10	Surviving the storm: Dealing with COVID-19. Cellular Immunology, 2020, 354, 104153.	1.4	4
11	Spleen participation in partial MHC class II construct neuroprotection in stroke. CNS Neuroscience and Therapeutics, 2020, 26, 663-669.	1.9	13
12	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. Metabolic Brain Disease, 2019, 34, 1705-1712.	1.4	8
13	Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE. Journal of Neuroinflammation, 2019, 16, 195.	3.1	15
14	A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury. Journal of Neuroinflammation, 2019, 16, 14.	3.1	25
15	Increased CD74 binding and EAE treatment efficacy of a modified DRÎ±1 molecular construct. Metabolic Brain Disease, 2019, 34, 153-164.	1.4	10
16	Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells. Metabolic Brain Disease, 2018, 33, 1599-1607.	1.4	29
17	Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice. Journal of Neuroimmunology, 2017, 305, 59-67.	1.1	33
18	Sex-dependent treatment of chronic EAE with partial MHC class II constructs. Journal of Neuroinflammation, 2017, 14, 100.	3.1	14

#	Article	IF	Citations
19	Sex differences in regulatory cells in experimental stroke. Cellular Immunology, 2017, 318, 49-54.	1.4	34
20	DRÎ±1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury. Metabolic Brain Disease, 2017, 32, 1395-1402.	1.4	15
21	DRÎ±1-MOG-35-55 Reduces Permanent Ischemic Brain Injury. Translational Stroke Research, 2017, 8, 284-293.	2.3	25
22	MIF and D-DT are potential disease severity modifiers in male MS subjects. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8421-E8429.	3.3	83
23	Estrogen protects both sexes against EAE by promoting common regulatory cell subtypes independent of endogenous estrogen. Metabolic Brain Disease, 2017, 32, 1747-1754.	1.4	24
24	Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells. Journal of Neuroimmunology, 2017, 310, 51-59.	1.1	47
25	Partial MHC class II constructs as novel immunomodulatory therapy for stroke. Neurochemistry International, 2017, 107, 138-147.	1.9	17
26	Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke. Neurochemistry International, 2017, 107, 148-155.	1.9	18
27	Role of MIF in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. , 2017, , 97-107.		0
28	Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74. Cytokine, 2016, 88, 62-70.	1.4	18
29	Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2016, 293, 45-53.	1.1	49
30	Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Metabolic Brain Disease, 2016, 31, 249-255.	1.4	33
31	HLA-DRÎ±1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. Journal of Neuroinflammation, 2015, 12, 123.	3.1	30
32	IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. Journal of Neuroimmunology, 2015, 285, 129-136.	1.1	26
33	The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metabolic Brain Disease, 2015, 30, 877-884.	1.4	2
34	Regulatory CD8+CD122+ T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells. Metabolic Brain Disease, 2015, 30, 911-924.	1.4	46
35	Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice. Metabolic Brain Disease, 2015, 30, 1117-1127.	1.4	33
36	PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke, 2015, 46, 2926-2934.	1.0	36

#	Article	IF	Citations
37	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Frontiers in Cellular Neuroscience, 2014, 8, 228.	1.8	11
38	Multiâ€analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis <scp>C</scp> virus infection. Brain and Behavior, 2014, 4, 123-142.	1.0	36
39	A novel HLA-DRÎ±1-MOG-35-55 construct treats experimental stroke. Metabolic Brain Disease, 2014, 29, 37-45.	1.4	25
40	Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metabolic Brain Disease, 2014, 29, 59-73.	1.4	73
41	Novel Humanized Recombinant T Cell Receptor Ligands Protect the Female Brain After Experimental Stroke. Translational Stroke Research, 2014, 5, 577-585.	2.3	36
42	HLA-DRÎ±1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2014, 192, 4164-4173.	0.4	48
43	IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metabolic Brain Disease, 2013, 28, 375-386.	1.4	129
44	A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. Journal of Autoimmunity, 2013, 40, 96-110.	3.0	41
45	Partial <scp>MHC</scp> class <scp>II</scp> constructs inhibit <scp>MIF</scp>/<scp>CD</scp>74 binding and downstream effects. European Journal of Immunology, 2013, 43, 1309-1321.	1.6	54
46	The HLA-DRB1*15. Journal of the American Society of Nephrology: JASN, 2013, 24, 419-431.	3.0	66
47	Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction. PLoS ONE, 2013, 8, e56306.	1.1	17
48	PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. Journal of Clinical & Cellular Immunology, 2013, 04, 143.	1.5	58
49	Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Diseases, 2012, 2012, 1-11.	2.7	33
50	Neuroprotective Effects of Recombinant T-cell Receptor Ligand in Autoimmune Optic Neuritis in HLA-DR2 Mice. , 2012, 53, 406.		16
51	Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis. Metabolic Brain Disease, 2012, 27, 143-149.	1.4	6
52	Regulatory T cells play a role in Tâ€cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis. Immunology, 2012, 135, 168-179.	2.0	3
53	Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metabolic Brain Disease, 2012, 27, 7-15.	1.4	47
54	RTL therapy for multiple sclerosis: A Phase I clinical study. Journal of Neuroimmunology, 2011, 231, 7-14.	1.1	37

#	Article	IF	Citations
55	Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. Translational Stroke Research, 2011, 2, 404-410.	2.3	21
56	Estrogenâ€induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. European Journal of Immunology, 2011, 41, 1165-1175.	1.6	83
57	TCRâ€like antibodies distinguish conformational and functional differences in twoâ€versus fourâ€domain auto reactive MHC class IIâ€“peptide complexes. European Journal of Immunology, 2011, 41, 1465-1479.	1.6	12
58	Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE Induced by Recombinant Human MOG. Journal of NeuroImmune Pharmacology, 2010, 5, 231-239.	2.1	19
59	Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2010, 225, 52-61.	1.1	27
60	Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4⁺â€ƒFoxP3⁺ Tâ€regulatory cells suppress interleukinâ€2â€dependent expansion of myelin basic proteinâ€specific T cells. Immunology, 2010, 130, 114-124.	2.0	4
61	Characterization of human platelet binding of recombinant T cell receptor ligand. Journal of Neuroinflammation, 2010, 7, 75.	3.1	16
62	Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand. Journal of Neuroscience, 2009, 29, 3816-3823.	1.7	30
63	Recombinant T Cell Receptor Ligand Treats Experimental Stroke. Stroke, 2009, 40, 2539-2545.	1.0	78
64	Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. Journal of Neuroimmunology, 2009, 215, 125-128.	1.1	90
65	Oestrogen modulates experimental autoimmune encephalomyelitis and interleukinâ€17 production via programmed death 1. Immunology, 2009, 126, 329-335.	2.0	116
66	Therapeutic vaccination with a trivalent Tâ€cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology, 2008, 123, 66-78.	2.0	60
67	Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?. Immunology, 2008, 125, 1-13.	2.0	37
68	Autologous T-Cell Vaccination forÂMultiple Sclerosis. BioDrugs, 2008, 22, 265-273.	2.2	31
69	MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis. Journal of Immunology, 2008, 180, 1249-1257.	0.4	21
70	Recombinant Î Cell Receptor Ligands: Immunomodulatory, Neuroprotective and Neuroregenerative Effects Suggest Application as Therapy for Multiple Sclerosis. Reviews in the Neurosciences, 2008, 19, 327-39.	1.4	18
71	Functional Suppression by FoxP3⁺CD4⁺CD25^{high}Regulatory T Cells during Acute Hepatitis C Virus Infection. Journal of Infectious Diseases, 2008, 197, 46-57.	1.9	84
72	A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS. Journal of Neuroscience, 2007, 27, 12531-12539.	1.7	50

#	Article	IF	Citations
73	Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). International Immunology, 2007, 19, 337-343.	1.8	202
74	Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate, 2007, 67, 1019-1028.	1.2	20
75	Monomeric DR2/MOG-35â€“55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clinical Immunology, 2007, 123, 95-104.	1.4	19
76	Trivalent T Cell Receptor Peptide Vaccine for Treatment of Multiple Sclerosis Targets Predominant V Genes Widely Implicated in Autoimmune Diseases and Allergy. , 2007, , 369-408.		1
77	Splenic Atrophy in Experimental Stroke Is Accompanied by Increased Regulatory T Cells and Circulating Macrophages. Journal of Immunology, 2006, 176, 6523-6531.	0.4	367
78	Experimental models for demyelinating diseases. , 2006, , 393-410.		0
79	Antigen-Specific Therapy Promotes Repair of Myelin and Axonal Damage in Established EAE. Journal of Neurochemistry, 2006, 98, 1817-1827.	2.1	48
80	Experimental Stroke Induces Massive, Rapid Activation of the Peripheral Immune System. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 654-665.	2.4	483
81	Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway. Journal of Neuroscience Research, 2006, 84, 370-378.	1.3	205
82	Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands. , 2006, 47, 2555.		22
83	Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells. Journal of Immunology, 2006, 177, 3874-3883.	0.4	39
84	Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. Journal of Chemical Technology and Biotechnology, 2005, 80, 2-12.	1.6	13
85	Decreased FOXP3 levels in multiple sclerosis patients. Journal of Neuroscience Research, 2005, 81, 45-52.	1.3	323
86	TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR-Specific CD4+CD25+ Treg Cells. Inflammation and Allergy: Drug Targets, 2005, 4, 217-229.	3.1	36
87	Middle-Age Male Mice Have Increased Severity of Experimental Autoimmune Encephalomyelitis and Are Unresponsive to Testosterone Therapy. Journal of Immunology, 2005, 174, 2387-2395.	0.4	78
88	Identification of HLA-DRB1*1501â€“Restricted T-cell Epitopes from Prostate-Specific Antigen. Clinical Cancer Research, 2005, 11, 2853-2861.	3.2	28
89	Treatment of Passive Experimental Autoimmune Encephalomyelitis in SJL Mice with a Recombinant TCR Ligand Induces IL-13 and Prevents Axonal Injury. Journal of Immunology, 2005, 175, 4103-4111.	0.4	37
90	Congruent Effects of Estrogen and T-Cell Receptor Peptide Therapy on Regulatory T Cells in EAE and MS. International Reviews of Immunology, 2005, 24, 447-477.	1.5	18

#	Article	IF	Citations
91	Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment. Journal of Immunology, 2004, 173, 2227-2230.	0.4	454
92	Monomeric Recombinant TCR Ligand Reduces Relapse Rate and Severity of Experimental Autoimmune Encephalomyelitis in SJL/J Mice through Cytokine Switch. Journal of Immunology, 2004, 172, 4556-4566.	0.4	49
93	Myelin oligodendrocyte glycoprotein-35â€“55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. European Journal of Immunology, 2004, 34, 1251-1261.	1.6	61
94	Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. Journal of Neuroscience Research, 2004, 76, 129-140.	1.3	32
95	T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. Journal of Neuroscience Research, 2004, 77, 670-680.	1.3	13
96	HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes. Journal of Neuroscience Research, 2004, 78, 100-114.	1.3	15
97	T Lymphocytes Do Not Directly Mediate the Protective Effect of Estrogen on Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2004, 165, 2069-2077.	1.9	55
98	Endogenous CD4+BV8S2? T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG?/? mice. Journal of Neuroscience Research, 2003, 71, 89-103.	1.3	13
99	CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2003, 73, 667-678.	1.3	23
100	Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. Journal of Neuroscience Research, 2003, 74, 296-308.	1.3	184
101	The Protective Effect of 17Î²-Estradiol on Experimental Autoimmune Encephalomyelitis Is Mediated through Estrogen Receptor-Î±. American Journal of Pathology, 2003, 163, 1599-1605.	1.9	167
102	Recombinant TCR Ligand Induces Early TCR Signaling and a Unique Pattern of Downstream Activation. Journal of Immunology, 2003, 171, 1934-1940.	0.4	46
103	Recombinant TCR Ligand Induces Tolerance to Myelin Oligodendrocyte Glycoprotein 35-55 Peptide and Reverses Clinical and Histological Signs of Chronic Experimental Autoimmune Encephalomyelitis in HLA-DR2 Transgenic Mice. Journal of Immunology, 2003, 171, 127-133.	0.4	83
104	17?-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2001, 65, 529-542.	1.3	125
105	Diminished frequency of interleukin-10-secreting, T-cell receptor peptide-reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene. Journal of Neuroscience Research, 2001, 66, 171-176.	1.3	16
106	TCR peptide therapy in human autoimmune diseases. Neurochemical Research, 2001, 26, 713-730.	1.6	43
107	Low-Dose Estrogen Therapy Ameliorates Experimental Autoimmune Encephalomyelitis in Two Different Inbred Mouse Strains. Journal of Immunology, 2001, 166, 2080-2089.	0.4	311
108	Rudimentary TCR Signaling Triggers Default IL-10 Secretion by Human Th1 Cells. Journal of Immunology, 2001, 167, 4386-4395.	0.4	53

#	Article	IF	Citations
109	Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops. Critical Reviews in Immunology, 2000, 20, 28.	1.0	7
110	Regulation of Encephalitogenic T Cells with Recombinant TCR Ligands. Journal of Immunology, 2000, 164, 6366-6371.	0.4	38
111	Treatments targeting the T cell receptor (TCR): effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells. Seminars in Immunopathology, 1999, 21, 77-90.	4.0	7
112	Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. , 1999, 55, 432-440.		41
113	T Cell Receptor V Genes in Multiple Sclerosis: Increased Use of TCRAV8 and TCRBV5 in MBP-Specific Clones. International Reviews of Immunology, 1999, 18, 9-36.	1.5	21
114	Immunoregulation of Encephalitogenic MBP-NAc1-11-Reactive T Cells by CD4+ TCR-Specific T Cells Involves IL-4, IL-10 and IFN-Î³. Autoimmunity, 1999, 31, 237-248.	1.2	14
115	Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. Journal of Neuroscience Research, 1998, 52, 420-426.	1.3	68
116	Neonatal exposure of TCR BV8S2 transgenic mice to recombinant TCR BV8S2 results in reduced T cell proliferation and elevated antibody response to BV8S2, and increased severity of EAE. , 1998, 52, 750-756.		7
117	Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide. Immunology and Cell Biology, 1998, 76, 83-90.	1.0	4
118	Myelin basic crotein-specific and TCR V?8.2-Specific T-cell lines from TCR V?8.2 transgenic mice utilize the same V? and V? genes: specificity associated with the V? CDR3-J? region. Journal of Neuroscience Research, 1997, 47, 489-499.	1.3	16
119	Treatment of multiple sclerosis with Tâ€“cell receptor peptides: Results of a doubleâ€“blind pilot trial. Nature Medicine, 1996, 2, 1109-1115.	15.2	175
120	Human Cd8+ T Cell Clone Regulates Autologous Cd4+ Myelin Basic Protein Specific T Cells. Autoimmunity, 1992, 14, 111-119.	1.2	7
121	Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. Journal of Neuroimmunology, 1992, 38, 105-113.	1.1	162
122	Ganglioside modulation of CD4 does not block T-helper cell function as compared to antagonism by anti-CD4 antibody. Drug Development Research, 1992, 25, 315-323.	1.4	3
123	Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature, 1989, 341, 541-544.	13.7	615
124	Myelin basic protein binding cells in active multiple sclerosis. Annals of Neurology, 1979, 6, 8-12.	2.8	18
125	Transfer factor therapy in patients with cancer. Cancer, 1976, 37, 90-97.	2.0	30